Sue Hughes March 11, 2002 Mon, 11 Mar 2002 21:00:00 ...

The FDA said it does not know how clarithromycin might cause heart problems or death, but it’s been warning about the problem since 2005. And review of data 10 years later shows heart patients ...

Clarithromycin release from each tablet or capsule was measured in vitro using USP dissolution apparatus 2 operated at 50 rpm, 37°C, using 900ml 0.1 mol/L acetate buffer (pH 5) as the dissolution ...

These patients were also newly prescribed clarithromycin (n = 6,592; 43% aged 76 to 85 years; 49% women), which was the exposure of interest, or azithromycin (n = 18,351; 43% aged 76 to 85 years ...

The US Food and Drug Administration (FDA) is alerting clinicians to the possibility of greater risks of cardiovascular morbidity and mortality in patients with heart disease who are prescribed ...

Clarithromycin resistance in 102 patients within the Seattle area with detectable 23S rRNA. Prevalance of antibiotic resistance was highest among Asians. Figure by Yiting Lim Since culture-based ...

Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP Ranbaxy One of Few Companies to Offer Both Suspension and Tablet Forms PRINCETON, N.J., Oct. 2 -- ...

Clarithromycin-based triple therapies across these studies showed eradication rates of approximately 60%, while rapid CYP2C19 metabolizers had eradication rates of less than 20%.

We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 ...